//
sign in
Post
by @danabra.mov
PostEmbed
by @danabra.mov
Record
by @jimpick.com
Record
by @atsui.org
+ new component
Post
🦴🚨 The FDA has accepted the BLA for ozekibart (INBRX-109) in patients with unresectable or metastatic conventional chondrosarcoma, marking a major regulatory milestone in a disease with no approved systemic therapies. Read more ➡️ www.onclive.com/view/fda-acc... #Sarcoma #Chondrosarcoma #Oncology
20h
The FDA has accepted a BLA for ozekibart in unresectable or metastatic conventional chondrosarcoma, setting a PDUFA goal date of April 14, 2027.
www.onclive.com
FDA Accepts BLA for Ozekibart in Conventional Chondrosarcoma | OncLive
OncLive